学术时政｜庄辉：慢性HBV感染免疫耐受期应否治疗？

慢特质HBV狂犬病感染特异特质耐受期患病患是否应将该不感兴趣治疗法是现在国际间学术特质界争议较大、名气很颇高的一个缺陷。英美两国、东欧及亚太手册一般不破亦然对特异特质耐受期慢特质爱滋患病应治疗法，但有多位历史学家建议对HBV狂犬病感染特异特质耐受期患病患透过抗生素治疗法。

针对这一热点在实践中缺陷，《诊疗肠胆患病时尚杂志》特置“学术特质时评”娱乐节目，并邀请庄辉讲师撰文与大家一起辩论，作为开始，不是断定。本刊热诚欢迎广大读者就此公共政策踊跃积极参与辩论，来稿将陆续刊登。

无论如何，本刊将“学术特质时评”置为长期以来固定娱乐节目，以缺陷为导向，大力学术特质公正、公平，百家时评，百花齐放，在秉持学术特质民主运动的思辨中的探讨真理，为推动本学科学术特质时评尽应将有职能。

至少，全球慢特质HBV狂犬病携带者平原则上2.92亿人，其中的特异特质耐受期患病患平原则上1.98亿［1］。我国慢特质HBV狂犬病携带者平原则上8600万亦然，其中的特异特质耐受期患病患平原则上3230万［1］。

现在英美两国［2］、东欧［3］和亚太［4］肠患病学不会披露的慢特质爱滋患病（CHB）看病手册（表列全称英美两国手册、东欧手册和亚太手册）关于特异特质耐受期CHB（IT-CHB）患病患的判别及治疗法的破亦然对此不完全一致：英美两国手册［2］中的ALT经常性值时限（ULN）年长者为30 U/L，妇女为25 U/L；东欧和亚太手册中的ALT ULN男同志原则上为40 U/L。关于IT-CHB判别，英美两国手册：HBV DNA＞106 IU/ml，ALT经常性；东欧手册：HBV DNA＞107 IU/ml，ALT持续经常性；亚太手册：HBV DNA＞20 000 IU/ml，ALT 1~2×ULN。关于IT-CHB治疗法的破亦然对此，英美两国和亚太手册原则上只破亦然对肠切片辨识中的度/重度瘙痒（A3）或轻微血栓（F2）的IT-CHB患病患治疗法；东欧手册则破亦然扩展到IT-CHB治疗法指征：即成年＞30岁，或有肠细胞肿瘤（HCC）/败血症历史名人，或有肠外表现的IT-CHB患病患，即使ALT和肠切片经常性，也可以治疗法。

2020年5年底，Jeng等［5］在“应将否扩展到CHB治疗法指征”一文中的指出，对有活动特质/进展特质肠患病结论的灰区（即HBV DNA＜106 IU/ml）或成年＞40岁的IT-CHB患病患透过抗生素治疗法，较英美两国手册扩展到了治疗法指征。2020年9年底，中的国中韩和日本国10名技术人员联合刊载关于重新启动CHB治疗法东亚地区技术人员对此［6］，破亦然ALT ULN年长者为30 U/L，妇女为19 U/L，对ALT≥1×ULN患病患，破亦然抗生素治疗法。该技术人员对此扩展到了远比一部分IT-CHB患病患的抗生素治疗法。

英美两国、东欧和亚太手册不破亦然对IT-CHB治疗法的先前是：（1）IT-CHB是良特质患病因期，不引发败血症和HCC或引发率很极低［7-12］；（2）IT-CHB患病患的肠患狂犬病学无或轻微瘙痒和/或血栓［2,9,13-14］；（3）治果负，仅仅引发HBeAg毒素学匹配或HBsAg变为［5,15-19］；可自发特异特质控制达到HBeAg毒素学匹配［8,20-21］；（4）IT-CHB患病患多为青少年，对长期以来抗生素治疗法依从特质负，须要注意引发脑膜炎［12,22］。

2015年，Bertoletti等［23］对HBV狂犬病感染特异特质耐受期观念指出异议，确信这是据闻观念，缺乏特异特质学结论。2016年，Gastroenterology时尚杂志小组织技术人员对“特异特质耐受期观念”透过了辩论［24-28］。Bertoletti等［23-25,28］确信不应将特指IT-CHB，建议改回“颇高激活极低瘙痒期（HRLI）”，先前是：（1）在早产一时期已存在效应将和调节特异特质须要要的话；（2）婴幼儿和小孩可产生患狂犬病特异特质T特异特质细胞须要要的话；（3）婴幼儿和小孩的特异特质本身并无缺陷；（4）儿童在1岁内服用爱滋患病疫苗接种有效地；（5）不上半年爱滋患病患病患（最主要特异特质耐受期）原则上有HBV特异特质T特异特质细胞须要要的话、HBV DNA整合和莱卡肠细胞扩增，概述肠肿瘤引发早已重新启动。但Milich［26］和Liaw等［27］确信将IT-CHB改为HRLI的结论唯不充分。2017年东欧手册首先将IT-CHB月改为“HBeAg无症状慢特质HBV狂犬病感染”。

自2018年以来，值得注意是2020年，多位历史学家［29-33］指出，应将对HBV特异特质耐受期患病患治疗法，以增加其引发败血症和HCC的高风险，先前如下。

Mason等［24］检测26亦然慢特质HBV狂犬病携带者，其中的9亦然IT-CHB患病患、10亦然HBeAg无症状CHB患病患、7亦然HBeAg特征特质CHB患病患，挖掘出IT-CHB患病患与HBeAg无症状和特征特质CHB患病患一样，也可检测到HBV DNA整合、肠细胞突变、莱卡肠细胞扩增、HBV特异特质T特异特质细胞须要要的话以及肠脏破损。Chu等［8］随访240亦然IT-CHB患病患17年，败血症不会有引发率为12.6%。Chen等［34］随访251亦然IT-CHB患病患13年，HCC不会有引发率为5.1%。Beasley等［35］实用价值随访22 707亦然40~59岁中的国台湾年长者，其中的15.2%为HBsAg携带者，平原则上随访3.3年，HBsAg携带者的HCC发患病率（1158/10都来年）总体略颇高于非携带者（5/10都来年）。Sun等［36］研究成果我国161个患病因追踪点1990年—2014年的HCC患患病率资料挖掘出，无论是城市还是农村，年长者和妇女HCC患患病率原则上随成年下降而轻微急剧增颇高，值得注意是在30岁日后（三幅1）。HCC的引发是一个长期以来转变致患病步骤，概述早在30岁以前HCC引发早已重新启动［35］。

三幅1 我国1990年—2014年161个患病因追踪点财税男同志HCC成年失踪专率［36］

Kim等［37］研究成果中韩一所三甲的医院2000年—2013年患病亦然表头，其中的并未治疗法的IT-CHB患病患413亦然、嘌呤(硫)类似物（NAs）治疗法的特异特质活动期CHB患病患1497亦然，结果辨识，并未治疗法的IT-CHB患病患10年不会有HCC发患病率和失踪/肠移植引发率（并列12.7%和9.7%）总体略颇高于治疗法的特异特质活动期CHB患病患（并列6.1%和3.4%）（P值并列0.001、0.001）。

既往虽有路透社［2,9,13-14］，IT-CHB患病患的肠患狂犬病学无或轻微瘙痒和/或血栓，但近年来有多篇路透社［9,38-44］得出结论，28%~49%的IT-CHB患病患有轻微的肠细胞瘙痒发炎和肠血栓（≥G2/S2）患法药理学偏离（表1）。

既往曾路透社［5,15-19］，IT-CHB患病患不感兴趣抗生素治果偏颇高，仅仅引发HBeAg毒素学匹配或HBsAg变为。但近年来有多项研究成果［45-47］辨识，应将用NAs治疗法IT-CHB患病患，虽然HBeAg毒素学匹配或HBsAg变为率极低，但增加毒素HBV DNA素质效果总体。Chan等［45］用替诺福韦酯（TDF）或TDF/恩曲他浜（FTC）分别治疗法64亦然和62亦然IT-CHB患病患，平原则上成年为33岁，89%为亚洲人，B和C基因型占93%，99%为HBeAg无症状，HBV DNA素质为8.41 log10 IU/ml,治疗法至192就有，TDF小组55%(35/64)、TDF/FTC小组76%(47/62) 患病患的HBV DNA素质减至＜69 IU/ml，与基线远比有总体关联特质（P=0.016）。Pan等［46］和Jourdain等［47］曾多次在IT-CHB产妇中的，推展TDF公共卫生HBV女童传播的高血压研究成果，将IT-CHB产妇随机细分治疗法小组和非常少，Pan等［46］于孕30~32周至产妇4周，Jourdain等［47］于孕28周至产妇2周，分别应各小组产妇TDF或安慰剂，受孕时（即治疗法8~12周）检测所有产妇HBV DNA，结果辨识TDF小组HBV DNA素质分别增颇高4.7 log IU/ml和4.0 log IU/ml，而安慰剂小组HBV DNA素质无增颇高，仍维持在基线素质。中韩Chang等［48］推展了一项全国特质多中的心回顾特质研究成果，研究成果2006年1年底—2016年3年底中韩8所大型的医院共计484亦然IT-CHB患病患（HBeAg无症状、HBV DNA素质＞20 000 IU/ml，ALT素质＜40 U/L、无败血症），其中的87亦然不感兴趣抗生素治疗法，397亦然并未不感兴趣抗生素治疗法作为比对，经取向记分配对研究成果，10年间治疗法小组不会有HCC及败血症引发率总体极极低非常少（P值并列0.046、0.015）（三幅2）。

三幅2 中韩多中的心IT-CHB患病患抗生素治疗法回顾特质研究成果HCC及败血症不会有引发率［48］

HBV DNA素质是HCC引发的单一危险因素，增加毒素HBV DNA素质可总体增加HCC引发高风险。Chen等［49］对基于生态村1991年—1992年退小组的3653亦然（30~65岁）HBsAg无症状者实用价值表头，平原则上随访11.4年，挖掘出其不会有HCC引发率与退小组时HBV DNA素质有关，退小组时HBV DNA素质＜300、300~9999、10 000~99 999、100 000~999 999和≥1 000 000 拷贝/ml患病患HCC不会有引发率并列1.30%、1.37%、3.57%、12.17%和14.89%，随HBV DNA素质上升而总体急剧增颇高。

各国手册［2-4,50］反驳，治疗法CHB的最终目标是：有助于地长期以来抑制HBV激活，降极低肠细胞瘙痒发炎及肠脏纤维小组织增生，延缓和增加肠功能心肌梗塞、败血症失代偿、HCC和其他出血的引发，改善患病患与世隔绝能量密度，延长其生存环境时间，而不仅仅是为了个别HBV标志物的匹配或变为。因此，从增加败血症和HCC高风险来看，NAs治疗法IT-CHB患病患的效果是总体的。

（1）除此以外爱滋患病口服抗患病物恩替卡韦（ETV）、TDF、富马硫丙酚替诺福韦（TAF）长期以来治疗法安全和特质好、脑膜炎引发率极低［51-59］：ETV 5年不会有脑膜炎引发率仅为1.2%［53］；TDF 8年并未挖掘出脑膜炎［55］；TAF 3年无脑膜炎［58-59］。

（2）长期以来治疗法依从特质负，不能作为不治疗法的先前，因CHB患病患和其他慢特质患病因患病患也须要长期以来治疗法，治疗法的依从特质可通过健康教育等政策增加［31,60-61］。

（3）治疗法耐用特质颇高。现在爱滋患病抗患病物的治疗法经费极极低追踪经费，且IT-CHB患病患对追踪依从特质负。据路透社［19，62］，平原则上61%的HCC患病患为首次就诊，概述这些患病患既往并未不感兴趣追踪。

（4）对IT-CHB患病患抗生素治疗法可增加HBV素质传播和女童传播，并可增加爱滋患病歧视特质［46-47,63-64］。

（5）对IT-CHB患病患治疗法可增加爱滋患病诊断率和治疗法率［30，32，65］，借助于世界卫生小组织指出的到2030年扫除爱滋患病公共卫生后果的前提［66］。

鉴于（1） IT-CHB不是良特质患病因期；（2）对IT-CHB患病患治疗法可增加败血症和HCC的引发；（3）一线抗生素抗生素潜能强，脑膜炎引发率极低，长期以来治疗法安全和有效地；（4）治疗法经费极极低追踪经费，耐用特质颇高；（5）可增加HBV素质传播和女童传播，增加爱滋患病歧视特质；（6）可增加爱滋患病诊断率和治疗法率，借助于世界卫生小组织指出的到2030年扫除爱滋患病公共后果的前提。因此，应将扩展到对IT-CHB患病患的治疗法。同时，应将推展对IT-CHB患病患治疗法的研究成果，缺少更多的循证药理学结论，如（1）回顾特质实用价值表头研究成果：远比IT-CHB治疗法小组、并未治疗法小组和HBeAg无症状特异特质活动特质爱滋患病治疗法小组不会有败血症引发率、HCC发患病率、肠移植率及患患病率；（2）实用价值表头研究成果：远比3小组不会有败血症引发率、HCC发患病率、肠移植率及患患病率；（3）高血压研究成果：远比2小组不会有败血症引发率、HCC发患病率、肠移植率及患患病率等。

参考文献:

［1］Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study［J］. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403.

［2］TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance［J］. Hepatology, 2018, 67(4): 1560-1599.

［3］European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection［J］. J Hepatol, 2017, 67(2): 370-398.

［4］SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update［J］. Hepatol Int, 2016, 10(1): 1-98.

［5］JENG WJ, LOK AS. Should Treatment indications for chronic hepatitis B be expanded?［J］. Clin Gastroenterol Hepatol, 2020. ［Epub ahead of print］

［6］KAO JH, HU TH, JIA J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B［J］. Aliment Pharmacol Ther, 2020, 52(10): 1540-1550.

［7］CORNBERG M, LOK AS, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference［J］. J Hepatol, 2020, 72(3): 539-557.

［8］CHU CM, HUNG SJ, LIN J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels［J］. Am J Med, 2004, 116(12): 829-834.

［9］ANDREANI T, SERFATY L, MOHAND D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: Histologic findings and outcome［J］. Clin Gastroenterol Hepatol, 2007, 5(5): 636-641.

［10］LEE HW, KIM SU, BAATARKHUU O, et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals［J］. Sci Rep, 2019, 9(1): 2508.

［11］LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase［J］. Aliment Pharmacol Ther, 2020, 52(1): 196-204.

［12］LEE HW, KIM EH, LEE J, et al. Correction to: Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase［J］. Clin Transl Gastroenterol, 2020, 11(5): e00183.

［13］HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase［J］. Hepatology, 2007, 46(2): 395-401.

［14］MCMAHON BJ. Epidemiology and natural history of hepatitis B［J］. Semin Liver Dis, 2005, 25(Suppl 1): 3-8.

［15］WU IC, LAI CL, HAN SH, et al. Efficacy of entecir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage［J］. Hepatology, 2010, 51(4): 1185-1189.

［16］WONG VW, HUI AJ, WONG GL, et al. Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients［J］. J Clin Gastroenterol, 2018, 52(4): 347-352.

［17］ROSENTHAL P, LING SC, BELLE SH, et al. Combination of entecir/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection［J］. Hepatology, 2019, 69(6): 2326-2337.

［18］FELD JJ, TERRAULT NA, LIN HS, et al. Entecir and peginterferon alfa-2a in s with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection［J］. Hepatology, 2019, 69(6): 2338-2348.

［19］LEE HW, CHAN HL. Unresolved issues of immune tolerance in chronic hepatitis B［J］. J Gastroenterol, 2020, 55(4): 383-389.

［20］WU JF, SU YR, CHEN CH, et al. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children［J］. J Pediatr Gastroenterol Nutr, 2012, 54(1): 97-100.

［21］CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B［J］. Hepatology, 2010, 51(2): 435-444.

［22］DOLMAN GE, KOFFAS A, MASON WS, et al. Why, who and when to start treatment for chronic hepatitis B infection［J］. Curr Opin Virol, 2018, 30: 39-47.

［23］BERTOLETTI A, KENNEDY PT. The immune tolerant phase of chronic HBV infection: New perspectives on an old concept［J］. Cell Mol Immunol, 2015, 12(3): 258-263.

［24］MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant［J］. Gastroenterology, 2016, 151(5): 986-998.

［25］PROTZER U, KNOLLE P. “To Be or Not to Be”: Immune tolerance in chronic hepatitis B［J］. Gastroenterology, 2016, 151(5): 805-806.

［26］MILICH DR. The concept of immune tolerance in chronic hepatitis B virus infection is alive and well［J］. Gastroenterology, 2016, 151(5): 801-804.

［27］LIAW YF, CHU CM. Immune tolerance phase of chronic hepatitis B［J］. Gastroenterology, 2017, 152(5): 1245-1246.

［28］KENNEDY PTF, BERTOLETTI A, MASON WS. Reply to immune tolerance phase of chronic hepatitis B［J］. Gastroenterology, 2017, 152(5): 1246-1247.

［29］WONG GL. Management of chronic hepatitis B patients in immunetolerant phase: What latest guidelines recommend［J］. Clin Mol Hepatol, 2018, 24(2): 108-113.

［30］KLAIR JS, VANCURA J, MURALI AR. PRO: Patients with chronic hepatitis B in immune-tolerant phase should be treated［J］. Clin Liver Dis (Hoboken), 2020, 15(1): 21-24.

［31］HOWELL J, CHAN H, FELD JJ, et al. Closing the stable door after the horse has bolted: Should we be treating people with immune-tolerant chronic hepatitis B to prevent hepatocellular carcinoma?［J］. Gastroenterology, 2020, 158(8): 2028-2032.

［32］KOFFAS A, PETERSEN J, KENNEDY PT. Reasons to consider early treatment in chronic hepatitis B patients［J］. Antiviral Res, 2020, 177: 104783.

［33］KIM HL, KIM GA, PARK JA, et al. Cost-effectiveness of antiviral treatment in patients with immune-tolerant phase chronic hepatitis B［J］. Gut, 2020. ［Epub ahead of print］

［34］CHEN CF, LEE WC, YANG HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma［J］. Gastroenterology, 2011, 141(4): 1240-1248.

［35］BEASLEY RP, HWANG LY, LIN CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan［J］. Lancet, 1981, 2(8256): 1129-1133.

［36］SUN Y, WANG Y, LI M, et al. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: An age-period-cohort ysis［J］. BMJ Open, 2018, 8(2): e020490.

［37］KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B［J］. Gut, 2018, 67(5): 945-952.

［38］WANG C, DEUBNER H, SHUHART M, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection［J］. Hepatology, 2005, 42(Suppl 1): a573.

［39］LAI M, HYATT BJ, NASSER I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection［J］. J Hepatol, 2007, 47(6): 760-767.

［40］PARK JY, PARK YN, KIM DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels［J］. J Viral Hepat, 2008, 15(8): 615-621.

［41］KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT［J］. Gastroenterology, 2008, 134(5): 1376-1384.

［42］NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels［J］. Am J Gastroenterol, 2009, 104(9): 2206-2213.

［43］SETO WK, LAI CL, IP PP, et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B［J］. PLoS One, 2012, 7(2): e32622.

［44］LIAO B, WANG Z, LIN S, et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT［J］. PLoS One, 2013, 8(10): e78672.

［45］CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA［J］. Gastroenterology, 2014, 146(5): 1240-1248.

［46］PAN CQ, DUAN Z, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load［J］. N Engl J Med, 2016, 374(24): 2324-2334.

［47］JOURDAIN G, NGO-GIANG-HUONG N, HARRISON L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B［J］. N Engl J Med, 2018, 378(10): 911-923.

［48］CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide ogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study［J］. J Infect Dis, 2017, 216(11): 1407-1414.

［49］CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level［J］. JAMA, 2006, 295(1): 65-73.

［50］Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)［J］. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese)

中的华药理学不会狂犬病感染患病学年不会, 中的华药理学不会肠患病学年不会. 慢特质爱滋患病防治手册(2019年版)［J］. 诊疗肠胆患病时尚杂志, 2019, 35(12): 2648-2669.

［51］LAMPERTICO P, CHAN HL, JANSSEN HL, et al. Review article: Long-term safety of nucleoside and nucleotide ogues in HBV-monoinfected patients［J］. Aliment Pharmacol Ther, 2016, 44(1): 16-34.

［52］de VRIES-SLUIJS TE, REIJNDERS JG, HANSEN BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus［J］. Gastroenterology, 2010, 139(6): 1934-1941.

［53］TENNEY DJ, ROSE RE, BALDICK CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecir in nucleoside-nave patients is rare through 5 years of therapy［J］. Hepatology, 2009, 49(5): 1503-1514.

［54］KITRINOS KM, CORSA A, LIU Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B［J］. Hepatology, 2014, 59(2): 434-442.

［55］LIU Y, CORSA AC, BUTI M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment［J］. J Viral Hepat, 2017, 24(1): 68-74.

［56］LIU Y, MILLER MD, KITRINOS KM. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates invitro［J］. Antiviral Res, 2017, 139: 25-31.

［57］AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection［J］. J Hepatol, 2018, 68(4): 672-681.

［58］CATHCART AL, CHAN HL, BHARDWAJ N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection［J］. Antimicrob Agents Chemother, 2018, 62(10): e01064-18.

［59］CHAN HLY, MARCELLIN P, PAN CQ, et al. No resistance to tenofovir alafenamide detected through 144 weeks of treatment in patients with chronic hepatitis B［J］. Hepatology, 2018, 68(Suppl 1): 231A.

［60］COOKE GS, ANDRIEUX-MEYER I, APPLEGATE TL, et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology Simon Hepatology Commission［J］. Lancet Gastroenterol Hepatol, 2019, 4(2): 135-184.

［61］SCHREDER SE, PEDRANA A, SCOTT N, et al. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series［J］. Liver Int, 2019, 39(10): 1818-1836.

［62］ENRIQUEZ AD, CAMPBELL MS, REDDY KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis［J］. Aliment Pharmacol Ther, 2007, 26(3): 383-391.

［63］FREW PM, ALHANTI B, VO-GREEN L, et al. Multilevel factors influencing hepatitis B screening and vaccination among Vietnamese Americans in Atlanta, Georgia［J］. Yale J Biol Med, 2014, 87(4): 455-471.

［64］VEDIO A, LIU E, LEE A, et al. Improving access to health care for chronic hepatitis B among migrant Chinese populations: A systematic mixed methods review of barriers and enablers［J］. J Viral Hepat, 2017, 24(7): 526-540.

［65］KENNEDY P, LITWIN S, DOLMAN GE, et al. Immune tolerant chronic hepatitis B: The unrecognized risks［J］. Viruses, 2017, 9(5): 96.

［66］World Health Organization. Global Hepatitis Report［R/OL］. Geneva: WHO, 2017. 10.11.19.

本文撰稿人：葛俊

公众号撰稿人：胡翔宇